---
title: "Nanjing Leads Biolabs Starts Phase II Trial of Opamtistomig in Gastric Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283468085.md"
description: "Nanjing Leads Biolabs Co., Ltd. has initiated a Phase II clinical trial for its bispecific antibody Opamtistomig (LBL-024) targeting gastric cancer. The trial, led by Professor Shen Lin at Beijing Cancer Hospital, aims to evaluate the drug's efficacy and safety in patients with advanced gastric adenocarcinoma. Opamtistomig has shown promise in treating various tumors and has received regulatory designations in multiple regions. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$100.50, highlighting its potential in the competitive immuno-oncology market."
datetime: "2026-04-21T09:10:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283468085.md)
  - [en](https://longbridge.com/en/news/283468085.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283468085.md)
---

# Nanjing Leads Biolabs Starts Phase II Trial of Opamtistomig in Gastric Cancer

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) just unveiled an announcement.

Nanjing Leads Biolabs has begun a Phase II, open-label, multi-center clinical trial in China for its bispecific antibody Opamtistomig (LBL-024), enrolling the first patient with first-line locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Led by Beijing Cancer Hospital’s Professor Shen Lin, the study will assess the efficacy and safety of LBL-024 in this hard-to-treat population amid high gastric cancer incidence and poor survival rates in China.

LBL-024 simultaneously targets PD-L1 and 4-1BB to relieve immunosuppression and enhance T-cell activation, and it has already reached registrational stage globally for extrapulmonary neuroendocrine carcinoma with encouraging efficacy and safety data in multiple tumor types. The drug has secured multiple regulatory designations in China, the U.S. and Europe, underscoring its potential to become a first- or best-in-class broad-spectrum cancer therapy and to strengthen the company’s position in the competitive immuno-oncology field, though successful development and commercialization remain uncertain.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$100.50 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

**More about Nanjing Leads Biolabs Co., Ltd. Class H**

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative oncology therapies, including bispecific antibodies targeting immune checkpoints and T-cell activation pathways. Its pipeline targets multiple solid tumors and high unmet medical-need indications, with an emphasis on achieving first-in-class or best-in-class status in areas such as extrapulmonary neuroendocrine carcinoma and lung cancers.

**Average Trading Volume:** 827,049

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$18.69B

Find detailed analytics on 9887 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [09887.HK](https://longbridge.com/en/quote/09887.HK.md)

## Related News & Research

- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [13:19 ETCancerCheck and Evexia Partner to Make Early, Accurate Cancer Detection a Reality](https://longbridge.com/en/news/286448727.md)
- [Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies](https://longbridge.com/en/news/286741077.md)
- [14:00 ETMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma](https://longbridge.com/en/news/286951994.md)